SCHEDULE 13G/A: Samlyn Capital, LLC and Affiliates Disclose 9.8% Stake in Corvus Pharmaceuticals, Inc.

Samlyn Capital, LLC, along with Samlyn, LP and Robert Pohly, has reported a 9.8% beneficial ownership stake in Corvus Pharmaceuticals, Inc., totaling 6,667,105 shares of common stock as of December 31, 2024.

Summary

• Samlyn Capital, LLC, Samlyn, LP, and Robert Pohly collectively reported beneficial ownership of 6,667,105 shares of Corvus Pharmaceuticals, Inc. common stock.
• This ownership represents 9.8% of the total outstanding common stock of Corvus Pharmaceuticals, Inc.
• The reporting persons, Samlyn Capital, LLC, Samlyn, LP, and Robert Pohly, share both voting and dispositive power over all 6,667,105 beneficially owned shares.
• The shares were not acquired and are not held for the purpose of changing or influencing the control of Corvus Pharmaceuticals, Inc.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would significantly alter sentiment beyond the neutral implications of an institutional stake.

Positives

• The disclosure of a significant institutional investment by Samlyn Capital, LLC, holding 9.8% of Corvus Pharmaceuticals' common stock, may be viewed by the market as a sign of investor confidence or strategic interest in the company.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding the issuer's future performance or strategic direction.

Management Comments

• The reporting persons certify that, to the best of their knowledge and belief, the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, nor in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

This filing is a standard disclosure of beneficial ownership by an institutional investor and does not provide broader industry trend analysis or competitive insights.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by Samlyn Capital, LLC may influence investor sentiment and potentially the stock price of Corvus Pharmaceuticals, Inc.

Key Dates

Keywords

Corvus Pharmaceuticals, Samlyn Capital, Samlyn LP, Robert Pohly, Schedule 13G, beneficial ownership, common stock, institutional ownership, equity stake